Rhumbline Advisers Raises Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Rhumbline Advisers grew its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 6.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 440,351 shares of the biopharmaceutical company’s stock after acquiring an additional 28,383 shares during the period. Rhumbline Advisers owned about 0.14% of Amicus Therapeutics worth $3,593,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of FOLD. GAMMA Investing LLC raised its holdings in shares of Amicus Therapeutics by 1,610.8% during the first quarter. GAMMA Investing LLC now owns 7,442 shares of the biopharmaceutical company’s stock valued at $61,000 after buying an additional 7,007 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of Amicus Therapeutics during the 4th quarter valued at $59,000. Neo Ivy Capital Management boosted its position in shares of Amicus Therapeutics by 501.6% in the 4th quarter. Neo Ivy Capital Management now owns 395,745 shares of the biopharmaceutical company’s stock valued at $3,727,000 after purchasing an additional 329,959 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Amicus Therapeutics by 96.9% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 958,671 shares of the biopharmaceutical company’s stock valued at $9,031,000 after buying an additional 471,902 shares in the last quarter. Finally, Vestal Point Capital LP acquired a new position in Amicus Therapeutics in the 4th quarter worth approximately $31,557,000.

Analysts Set New Price Targets

A number of analysts recently issued reports on FOLD shares. Wells Fargo & Company lowered their target price on Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating on the stock in a research note on Thursday, February 20th. Wall Street Zen lowered shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, May 5th. The Goldman Sachs Group lowered their price objective on Amicus Therapeutics from $12.00 to $9.00 and set a “neutral” rating on the stock in a research report on Friday, May 2nd. Needham & Company LLC reissued a “hold” rating on shares of Amicus Therapeutics in a research report on Thursday, February 20th. Finally, UBS Group lifted their price objective on Amicus Therapeutics from $21.00 to $22.00 and gave the company a “buy” rating in a report on Friday, May 2nd. Four equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, Amicus Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $16.22.

Amicus Therapeutics Stock Down 2.3%

FOLD stock opened at $6.03 on Friday. Amicus Therapeutics, Inc. has a 1-year low of $5.81 and a 1-year high of $12.65. The business’s 50 day simple moving average is $6.48 and its 200 day simple moving average is $8.32. The company has a current ratio of 3.39, a quick ratio of 2.42 and a debt-to-equity ratio of 2.01. The firm has a market capitalization of $1.86 billion, a PE ratio of -33.50, a PEG ratio of 1.51 and a beta of 0.54.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.